June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Urinary Mass Spectrometry Metabolomic Profiles in Age-related Macular Degeneration (AMD)
Author Affiliations & Notes
  • Deeba Husain
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ines Lains
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Kevin Milton Mendez
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Joao Q Gil
    Coimbra Univ, Portugal
  • rachel kelly
    Brigham and Women's Hospital Channing Division of Network Medicine, Boston, Massachusetts, United States
  • John B Miller
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Demetrios G. Vavvas
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ivana K Kim
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Joaquim Murta
    Coimbra Univ, Portugal
  • Liming Liang
    Harvard University T H Chan School of Public Health, Boston, Massachusetts, United States
  • Rufino Silva
    Coimbra Univ, Portugal
  • Jessica Lasky-Su
    Brigham and Women's Hospital Channing Division of Network Medicine, Boston, Massachusetts, United States
  • Joan W Miller
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Deeba Husain Allergan, Genetech, Novartis, Omeicos Therapeutics, Code C (Consultant/Contractor); Ines Lains None; Kevin Mendez None; Joao Gil None; rachel kelly None; John Miller Alcon, Allergan, Carl Zeiss, Sunovion, Genentech, Code C (Consultant/Contractor); Demetrios Vavvas Valitor, Olix Pharmaceutical, Code C (Consultant/Contractor); Ivana Kim None; Joaquim Murta None; Liming Liang None; Rufino Silva None; Jessica Lasky-Su None; Joan Miller Heidelberg Engineering, Sunivion, Kalvista Pharmaceuticls, Code C (Consultant/Contractor), Lowry Medical Research, Code F (Financial Support), ONL therapeutics, Code P (Patent), Aptinyx Inc, , Code S (non-remunerative)
  • Footnotes
    Support  R01EY030088
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 364 – F0195. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Deeba Husain, Ines Lains, Kevin Milton Mendez, Joao Q Gil, rachel kelly, John B Miller, Demetrios G. Vavvas, Ivana K Kim, Joaquim Murta, Liming Liang, Rufino Silva, Jessica Lasky-Su, Joan W Miller; Urinary Mass Spectrometry Metabolomic Profiles in Age-related Macular Degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2022;63(7):364 – F0195.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients with age-related macular degeneration (AMD) and across different severity stages have been shown to have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feasible and more accessible alternative to plasma biomarkers. However, to our knowledge, no studies have evaluated urinary mass spectrometry (MS) metabolomics in AMD. This study aimed to assess urinary metabolomic profiles of patients with different stages of AMD and a control group.

Methods : We conducted a prospectively designed, multicenter, cross-sectional study including patients with AMD and a control group (>50 years old). At our two study sites – Boston, US and Coimbra, Portugal – participants had a complete ophthalmological exam and were imaged with color fundus photographs for AMD classification and staging (AREDS classification scheme). At the same visit, fasting urine samples were collected, which were used for metabolomic profiling (Ultrahigh Performance Liquid chromatography – Mass Spectrometry, Metabolon, Inc). Multivariable logistic and ordinal logistic regression models were used for analysis, accounting for age, gender, body mass index and use of AREDS supplementation.

Results : We included 484 participants, 389 with AMD (89 early, 201 intermediate and 99 late AMD) and 95 controls. Six urinary metabolites differed significantly (p< 0.01) across the severity stages of AMD (early, intermediate and late stage) with pathway analysis revealing an enrichment of sphingolipid metabolism. Of note, two of the metabolites (sphingosine and phosphoethanolamine) have been previously shown by our group to also differ in the plasma of patients with AMD compared to controls and all across AMD severity stages.

Conclusions : This is the first investigation of urine metabolomics using Mass Spectrometry in AMD. We identified some differences across stages of disease that support our previous findings using plasma, supporting the potential of these metabolites as biomarkers for this common, blinding disease.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×